O

OrbiMed Portfolio holdings

AUM $5.4B Turnover 40.13%
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
Cap. Flow
+$275M
Cap. Flow %
2.78%
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24
Avg Time Held Equity + Options
1.7 years
Top 10 Avg Time Held Equity + Options
0.5 years
Top 20 Avg Time Held Equity + Options
1.6 years
Avg Time Held Equity only
1.7 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
1.6 years

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$123M
2
NPCE icon
Neuropace
NPCE
+$93.1M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$77.8M
4
JANX icon
Janux Therapeutics
JANX
+$77.2M
5
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$94.6M
2
ABCL icon
AbCellera Biologics
ABCL
+$54.5M
3
ADVM icon
Adverum Biotechnologies
ADVM
+$54.2M
4
MOH icon
Molina Healthcare
MOH
+$38M
5
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Miscellaneous 4.15%
3 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SWTX icon
1
DELISTED
SpringWorks Therapeutics
SWTX
$498M 5.04%
6,044,266
-142,041
-2% -$10.8M
2019 Q3
7 quarters
BMY icon
2
Bristol-Myers Squibb
BMY
$121B
$302M 3.05%
4,515,400
– –
2019 Q4
6 quarters
EWTX icon
3
Edgewise Therapeutics
EWTX
$4.02B
$297M 3.01%
13,944,680
– –
2021 Q1
1 quarter
BSX icon
4
Boston Scientific
BSX
$62.3B
$296M 2.99%
6,920,600
– –
2014 Q1
29 quarters
MRK icon
5
Merck
MRK
$364B
$290M 2.94%
3,732,400
-179,155
-5% -$13.3M
2016 Q1
21 quarters
PRLD icon
6
Prelude Therapeutics
PRLD
$258M
$287M 2.91%
10,039,691
– –
2020 Q3
3 quarters
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$274M 2.77%
2,922,155
-222,200
-7% -$20.4M
2019 Q4
6 quarters
SPRY icon
8
ARS Pharmaceuticals
SPRY
$391M
$270M 2.73%
8,740,887
– –
2020 Q4
2 quarters
PMVP icon
9
PMV Pharmaceuticals
PMVP
$66.3M
$250M 2.53%
7,330,423
– –
2020 Q3
3 quarters
NTRA icon
10
Natera
NTRA
$56.9B
$234M 2.36%
2,057,800
-138,100
-6% -$14.1M
2015 Q3
23 quarters
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$126B
$215M 2.17%
1,065,400
-70,500
-6% -$14.7M
2013 Q2
32 quarters
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$204M 2.07%
1,264,200
+43,000
+4% +$6.9M
2019 Q3
7 quarters
TPTX
13
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$184M 1.86%
2,361,327
– –
2019 Q2
8 quarters
IOVA icon
14
Iovance Biotherapeutics
IOVA
$6.44B
$173M 1.75%
6,645,100
– –
2015 Q1
25 quarters
ARQT icon
15
Arcutis Biotherapeutics
ARQT
$3.32B
$166M 1.68%
6,073,850
– –
2020 Q1
5 quarters
UNH icon
16
UnitedHealth
UNH
$355B
$156M 1.58%
389,700
-13,300
-3% -$5.3M
2020 Q4
2 quarters
GH icon
17
Guardant Health
GH
$21.9B
$152M 1.54%
1,227,400
+250,000
+26% +$33.6M
2020 Q3
3 quarters
HUM icon
18
Humana
HUM
$51.3B
$148M 1.5%
335,000
+21,400
+7% +$9.35M
2019 Q3
7 quarters
ABCL icon
19
AbCellera Biologics
ABCL
$4.01B
$137M 1.38%
6,223,019
-1,977,749
-24% -$54.5M
2020 Q4
2 quarters
ABBV icon
20
AbbVie
ABBV
$501B
$132M 1.33%
1,167,500
-45,700
-4% -$5.15M
2020 Q1
5 quarters
ISRG icon
21
Intuitive Surgical
ISRG
$148B
$128M 1.3%
418,800
– –
2013 Q4
30 quarters
ELV icon
22
Elevance Health
ELV
$92.8B
$128M 1.3%
335,700
+49,100
+17% +$18.8M
2020 Q4
2 quarters
DXCM icon
23
DexCom
DXCM
$31.5B
$127M 1.28%
1,189,600
– –
2018 Q4
10 quarters
XBI icon
24
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$127M 1.28%
+935,700
New +$123M
2021 Q2
0 quarters
DCPH icon
25
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$121M 1.22%
3,297,301
+1,916,401
+139% +$74.2M
2017 Q3
15 quarters
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2021 Portfolio in Review

As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
  • OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
  • OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
  • OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
  • OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
  • OrbiMed opened 24 new positions and closed 24 in Q2 2021.
  • OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.